C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 403/06 (2006.01)
Patent
CA 2502914
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors of Formula (I), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
L'invention concerne des agonistes sélectifs efficaces du sous-type EP¿4? des récepteurs E2 de prostaglandine, l'utilisation de ces agonistes ou de préparations à base de ceux-ci dans le traitement du glaucome et d'autres états associés à une pression intra-oculaire élevée dans l'oeil d'un patient. L'invention concerne également l'utilisation des composés de l'invention dans la médiation des processus de modelage et de remodelage des ostéoblastes et des ostéoclastes.
Beunard Jean-Luc
Billot Xavier
Colucci John
Girard Mario
Han Yongxin
Merck Frosst Canada & Co./merck Frosst Canada & Cie
Merck Frosst Canada Ltd.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
2-pyrrolidones as ep4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-pyrrolidones as ep4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyrrolidones as ep4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1843738